{"id":3868,"date":"2017-02-04T10:45:03","date_gmt":"2017-02-04T10:45:03","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/"},"modified":"2026-10-12T15:49:06","modified_gmt":"2026-10-12T15:49:06","slug":"adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","title":{"rendered":"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs"},"content":{"rendered":"<p>Sygnature Discovery is a world-leading integrated drug discovery contract research organization with sites in the UK and Canada and headquarters in Nottingham (UK), serving biotech and pharma customers across the United States, Canada, the United Kingdom and Europe. We undertake hit identification, hit-to-lead and lead optimization projects and complete drug discovery programs across a range of therapeutic areas. In support of this, we have expanded our assay capability to include the state-of-the-art ImageXpress(R) Micro COnfocal (IXM-C) high-content imaging platform to provide multi-dimensional, high-throughput screening solutions to facilitate in-house drug profiling, bioscience and DMPK <em>in vitro<\/em> activities. Here we demonstrate the application of our integrated imaging platforms including the IXM-C and associated MetXppress(R) Image acquisition and analysis software to multiple phases of the drug discovery process.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":2500,"template":"","category":[1],"class_list":["post-3868","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.8 (Yoast SEO v28.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>High-Content Imaging for Drug Discovery | Scientific Poster<\/title>\n<meta name=\"description\" content=\"This poster shows how Sygnature applies IXM-C high-content imaging to screening, drug profiling, bioscience and in vitro DMPK activities. Learn more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs\" \/>\n<meta property=\"og:description\" content=\"This poster shows how Sygnature applies IXM-C high-content imaging to screening, drug profiling, bioscience and in vitro DMPK activities. Learn more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-12T15:49:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png\" \/>\n\t<meta property=\"og:image:width\" content=\"796\" \/>\n\t<meta property=\"og:image:height\" content=\"1128\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/\",\"name\":\"High-Content Imaging for Drug Discovery | Scientific Poster\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Screen-Shot-2018-03-08-at-10.34.29.png\",\"datePublished\":\"2017-02-04T10:45:03+00:00\",\"dateModified\":\"2026-10-12T15:49:06+00:00\",\"description\":\"This poster shows how Sygnature applies IXM-C high-content imaging to screening, drug profiling, bioscience and in vitro DMPK activities. Learn more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Screen-Shot-2018-03-08-at-10.34.29.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Screen-Shot-2018-03-08-at-10.34.29.png\",\"width\":796,\"height\":1128,\"caption\":\"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"alternateName\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.youtube.com\\\/@sygnature.discovery\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sygnature-discovery\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"High-Content Imaging for Drug Discovery | Scientific Poster","description":"This poster shows how Sygnature applies IXM-C high-content imaging to screening, drug profiling, bioscience and in vitro DMPK activities. Learn more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","og_locale":"fr_CA","og_type":"article","og_title":"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs","og_description":"This poster shows how Sygnature applies IXM-C high-content imaging to screening, drug profiling, bioscience and in vitro DMPK activities. Learn more.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","og_site_name":"Sygnature","article_modified_time":"2026-10-12T15:49:06+00:00","og_image":[{"width":796,"height":1128,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/","name":"High-Content Imaging for Drug Discovery | Scientific Poster","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","datePublished":"2017-02-04T10:45:03+00:00","dateModified":"2026-10-12T15:49:06+00:00","description":"This poster shows how Sygnature applies IXM-C high-content imaging to screening, drug profiling, bioscience and in vitro DMPK activities. Learn more.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Screen-Shot-2018-03-08-at-10.34.29.png","width":796,"height":1128,"caption":"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/adoption-high-content-imaging-capabilities-support-integrated-drug-discovery-programmes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Adoption of High Content Imaging Capabilities in Support of Integrated Drug Discovery Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","alternateName":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@sygnature.discovery","https:\/\/www.linkedin.com\/company\/sygnature-discovery\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":2,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3868\/revisions"}],"predecessor-version":[{"id":21018,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/3868\/revisions\/21018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2500"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=3868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=3868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}